Special Issue

Novel Imidazole Derivatives in Medicinal Chemistry

Message from the Guest Editors

Current concepts related to searching for new bioactive products, mainly including original active substances with potential application in pharmacy and medicine, are based on compounds with a previously determined structure, well-known properties and biological activity profile. Compounds containing the imidazole moiety exhibit a wide range of biological activities. The imidazole skeleton is present in various natural compounds, such as histidine, histamine and pilocarpine alkaloids, and synthetic bioactive compounds, including cimetidine, losartan, fungicides or herbicides. These azoles show a broad spectrum of biological activities, such as anticancer, antifungal, antiviral, antibacterial, antitubercular, antiparasitic, antihistaminic, anti-inflammatory and antineuropathic.

We invite researchers to publish their findings on the synthesis and biological applications of imidazole derivatives. This Special Issue aims to summarize the state of the art and the latest findings published in the imidazole field, as well as elucidate the future directions of these compounds in medicinal chemistry.

Guest Editors

Dr. Dorota Olender

Dr. Justyna Żwawiak

Prof. Dr. Lucjusz Zaprutko

Deadline for manuscript submissions

closed (25 July 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/177116

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

